Latest news with #CONMED
Yahoo
4 days ago
- Business
- Yahoo
Needham Downgrades CONMED Corporation (CNMD) to Hold from Buy
CONMED Corporation (NASDAQ:CNMD) is one of the best undervalued medical device stocks to buy now. On June 12, Needham downgraded CONMED Corporation (NASDAQ:CNMD) to Hold from Buy without a price target. Closeup portrait of a surgeon wearing a surgical mask and gown while holding a surgical device. The firm told investors in a research note that CONMED Corporation (NASDAQ:CNMD) is experiencing a drop in its long-term growth rate, primarily attributed to slower AirSeal and Buffalo Filter growth. It believes that slower revenue growth is likely to result in slower earnings growth and more gradual margin improvement for the company. The firm further reasoned that CONMED Corporation's (NASDAQ:CNMD) debt levels restrict its potential to repurchase shares or acquire new growth drivers. It contended that the company's outlook has deteriorated, and the shares are no longer at a discount provided that peer multiples have contracted. CONMED Corp (NASDAQ:CNMD) is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. Healthcare professionals, such as surgeons, use their products in a range of specialties, such as general surgery, orthopedics, thoracic surgery, gynecology, and gastroenterology. The company's product line comprises general surgery and orthopedic surgery. General surgery comprises endo-mechanical instrumentation primarily used for minimally invasive gastrointestinal and laparoscopic procedures. The orthopedic surgery product line comprises lower extremities, sports medicine implants and instrumentation, specialty-powered surgical instruments, and more. While we acknowledge the potential of CNMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
11-07-2025
- Business
- Yahoo
Lantheus, ICU Medical, Haemonetics, CONMED, and Astrana Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Medical Devices & Supplies - Imaging, Diagnostics company Lantheus (NASDAQ:LNTH) fell 3.1%. Is now the time to buy Lantheus? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company ICU Medical (NASDAQ:ICUI) fell 3.3%. Is now the time to buy ICU Medical? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Haemonetics (NYSE:HAE) fell 3.4%. Is now the time to buy Haemonetics? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Diversified company CONMED (NYSE:CNMD) fell 3.7%. Is now the time to buy CONMED? Access our full analysis report here, it's free. Healthcare Technology for Providers company Astrana Health (NASDAQ:ASTH) fell 3.3%. Is now the time to buy Astrana Health? Access our full analysis report here, it's free. CONMED's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. CONMED is down 23.3% since the beginning of the year, and at $51.67 per share, it is trading 33.4% below its 52-week high of $77.54 from November 2024. Investors who bought $1,000 worth of CONMED's shares 5 years ago would now be looking at an investment worth $708.88. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Business Wire
07-07-2025
- Business
- Business Wire
Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer
BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced that Martha Aronson will be stepping down from the company's Board of Directors to assume the role of President and Chief Executive Officer at Merit Medical, a global leader in the development, manufacture and distribution of proprietary medical devices. Mrs. Aronson's resignation from the Board will be effective July 7, 2025, as she transitions to her new leadership responsibilities. 'We are sincerely grateful to Martha for her years of dedicated service to CONMED,' said Pat Beyer, President and Chief Executive Officer of CONMED. 'Her guidance and expertise have been invaluable to our Board and to me personally as I stepped into the CEO role. We will miss her thoughtful leadership and wish her continued success in this exciting next chapter.' LaVerne Council, Chair of the Board of Directors, added, 'On behalf of the entire Board, I want to thank Martha for her outstanding contributions to CONMED. Her strategic insight and unwavering commitment to excellence have helped shape the company's direction and success. We wish her all the best as she takes on this new opportunity as President and CEO of Merit Medical.' Ms. Aronson joined the CONMED Board in February 2016 and served in various leadership capacities, including as Chair of the Board. Her tenure has been marked by a focus on strategic growth, governance excellence, and a deep commitment to the company's mission and values. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit Forward-Looking Statements This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Business Wire
02-07-2025
- Business
- Business Wire
CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025
LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the 'Investors' section of CONMED's website at The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit Forward-Looking Statements This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Yahoo
29-06-2025
- Business
- Yahoo
Is Now An Opportune Moment To Examine CONMED Corporation (NYSE:CNMD)?
While CONMED Corporation (NYSE:CNMD) might not have the largest market cap around , it received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$60.80 at one point, and dropping to the lows of US$47.66. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether CONMED's current trading price of US$52.17 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at CONMED's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Good news, investors! CONMED is still a bargain right now according to our price multiple model, which compares the company's price-to-earnings ratio to the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. we find that CONMED's ratio of 13.59x is below its peer average of 30.78x, which indicates the stock is trading at a lower price compared to the Medical Equipment industry. What's more interesting is that, CONMED's share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market. Check out our latest analysis for CONMED Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. However, with a relatively muted profit growth of 8.1% expected over the next couple of years, growth doesn't seem like a key driver for a buy decision for CONMED, at least in the short term. Are you a shareholder? Even though growth is relatively muted, since CNMD is currently trading below the industry PE ratio, it may be a great time to accumulate more of your holdings in the stock. However, there are also other factors such as capital structure to consider, which could explain the current price multiple. Are you a potential investor? If you've been keeping an eye on CNMD for a while, now might be the time to enter the stock. Its future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy CNMD. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed assessment. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example - CONMED has 3 warning signs we think you should be aware of. If you are no longer interested in CONMED, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
